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ABSTRACT
Objective: This study was designed to determine the correlation between Disease Activity Score (DAS 28) and the serum Cartilage Oligomeric Matrix 
Protein (COMP) levels in Indonesian Rheumatoid Arthritis (RA) patients. 
Methods: The subjects were patients who visit the rheumatology clinic at one governmental hospital in Bandung, Indonesia. DAS was determined 
by the QxMD Software based on erythrocyte sedimentation rate, and serum COMP levels were determined by enzyme-linked immunosorbent assay. 
Statistical analysis was conducted with IBM SPSS Statistics 23. 
Results: DAS 28 value was 3.36 ± 0.16 which indicates the moderate disease activity. Serum COMP levels were 843.80 ± 35.79 ng/ml in RA patients 
and 830.00 ± 48.92 ng/ml in normal controls. 
Conclusion: There is no correlation between DAS 28 and serum COMP levels in RA patients (p = 0.496 and rho = 0.129). 
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease 
which characterized by erosive arthritis in synovial joints symmetrically. 
It causes the pain, joint damage, malfunction, and decreased quality 
of life, even deformation [1]. The RA prevalence was various between 
populations, generally 0.5-1.0% of the population [2], it was 0.1-0.3% 
in Indonesia [3]. Early diagnosis and treatment of patients with RA are 
important to prevent the joint deformation [4].
Cartilage oligomeric matrix protein (COMP) is a potential biomarker 
to support the RA diagnosis [5]. COMP was contributed in assembly 
the collagen fiber type II in cartilage and in cooperation with other 
matrix proteins which stabilize the collagen network [6]. The serum 
COMP was correlated with disease activity score (DAS) 28-erythrocyte 
sedimentation rate (ESR) (p<0.05, r=0.40) in the RA early stages [7]. 
DAS demonstrates the RA stability to determine the appropriate 
treatment to relieve inflammation associated RA, slow or stop the joint 
damage that causes pain and deformation [8]. There are no studies 
about the correlation between DAS 28 and serum COMP levels, so this 
study was conducted to determine the correlation between DAS 28 and 
the serum COMP levels in RA patients.
SUBJECTS AND METHODS
Subjects
Cross-sectional study with prospective data collection. Subjects were 
recruited by consecutive sampling method after getting an explanation 
and signed the informed consent forms. The subject was divided into 
two groups, RA patients, and normal controls [9]. This study was 
conducted after approved by the Health Research Ethics Committee 
of Dr. Hasan Sadikin Hospital, Indonesia, No. LB.04.01/A05/EC/075 
III/2016.
The inclusion criteria are:
a. RA patients are the patients of the rheumatology clinic at one 
governmental hospital in Bandung City, Indonesia.
b. RA patients who meet at least 4 the clinical criteria from 2010 RA 
classification criteria [10] based on the rheumatologist examination 
without serology examination.
c. RA patients willing to participate in the present study by signed the 
informed consent and interviewed.
d. Patient’s age was over 18 years old.
The exclusion criteria are:
a. Patients who do not cooperate.
b. History of drug abuse, including alcoholism.
c. Patients with any other major medical disorder, i.e., diabetes mellitus, 
hypertension, chronic obstructive pulmonary disease, acute or 
chronic liver disease, acute or chronic kidney disease, tuberculosis, 
and systemic lupus erythematosus.
Methods
Determination of DAS 28
DAS 28 is calculated by application to calculate in QxMD Software.
Determination of serum COMP levels
The blood was collected from March to May 2016. The blood 
was taken from a peripheral vein and placed in a tube without 
ethylenediaminetetraacetic acid. Blood allowed to stand for 30 minutes 
to form a coagulant and centrifuged at 3000 rpm for 15 minutes. Serum 
is separated from the sediment and stored at −80°C. Serum COMP levels 
were determined by the following procedure in the Human COMP/
TSP5 enzyme-linked immunosorbent assay Pair Set (SEK10173) which 
purchased from Sino Biological Inc. (USA).
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Statistical analysis
Correlation between DAS 28 and serum COMP levels was analyzed 
using IBM SPSS Statistics 23.
RESULTS
All patients feel pain in the small joints of the hands, wrists, elbows, 
knees, and ankles. These facts were accorded with the joints that 
are common in RA [10]. All patients have worse joint stiffness in 
the morning and the evening. There was 16.67% of patients have 
hand deformities which change the hand function, reduced the grip 
strength, and complicated daily activities. Most patients (86.67%) had 
experienced the knee pain which reduces the ability to walk in long 
duration which interfering the patient activities. DAS was obtained 
from data of joint condition, ESR, and subjective patient assessment; 
then, DAS values were grouped by disease activity range (Table 1). DAS 
value was 3.36±0.16 (n=30), which means the category of moderate 
disease activity.
There is no correlation between DAS 28 and serum COMP levels 
(p=0.496 and rho=0.129).
DISCUSSION
Total RA patients were 80, but who meet the inclusion criteria only 
30 of patients, i.e., 4 of men (13.33%) and 26 of women (86.67%). All 
patients were interviewed for age, disease duration, how many joint 
with definite clinical synovitis (swelling), symmetrical arthritis, pain 
duration in the morning, drug therapy, medical treatment to reduce 
the pain such as surgery, and ancestry [9]. The results of present study 
are consistent with studies by Samanci et al., i.e., the RA incidence in 
women (87.43%) is seven times higher than men [11]. These results 
are different from the previous study in December 2014 to January 
2015 at the same location. The previous results were 24 of patients, 
i.e., 20 of women (83.33%) and 4 of men (16.67%) [9]. The different 
of number of RA patients who participate in this study showed that 
the increased awareness of RA patients to support the success of the 
RA treatment.
Age and gender (Table 2) are the confounding variable, i.e., the bias 
condition in estimating the variable effects in the RA incidence [12]. 
The higher RA incidence in women is due to hormones, especially 
estrogen. Estrogen is a factor that affects the autoimmune diseases, 
such as RA [13,14]. Estrogen and androgen have a very important 
role in the maturation of growing bones and prevent the losing the 
bone mass. Over the 30 years old, the female hormone estrogen 
tends to decrease. It made the estrogen deficiency which stimulates 
the imbalance of the bone remodeling activity because osteoblasts 
cannot compensate the osteoclasts work, so bone mass will 
decrease [15].
The age of RA incidence has a wide distribution, but the most common 
is in 40-50 years old [16]. In this study, the most RA incidence is in 
50-59 years old (Fig. 1). These results are different from the literature. 
We suggested the RA patients are less awareness of the importance of 
the RA early treatment to avoid the joint damage [17]. The interview 
data were shown that the patients visit a doctor after realizing that the 
body movement was abnormal. It was reflected the lack awareness of 
the RA symptoms. The RA patients were experiencing the severe pain 
when doing strenuous activities. The RA patients were reduced the 
pain by taking painkillers, such as paracetamol or diclofenac sodium. In 
Indonesia, RA was considered as an elderly disease, so there is lacked 
awareness for health monitoring because of joint pain for people who 
under 50 years old. In the previous study, the patients with higher 
education show a higher awareness for health monitoring [9].
Disease duration was used to determine the patient condition when 
the retrieved data. The shortest disease duration was 3 months, and 
the longest is 204 months (17 years). The common disease duration 
was 10-19 months (Fig. 2), and the average was 57.6±8.8 months. 
There is a wide range of disease duration, but the patient condition 
was varied, on the contrary, there was health improvement because of 
drug compliance. Most RA patients (80%) have experienced the joint 
pain for a minimum of three to nine months before a medical checkup. 
There was 16.67% of patient have bone deformities because of the 
retardation of early treatment.
At the first checkup, the patient will request to blood examination to 
determine the RA symptoms, i.e., ESR and rheumatoid factor. FR was 
only done on the first examination, whereas ESR was done every month 
or every three months to determine the inflammatory status. In this 
study, we were measured the serum COMP levels as a potential RA 
biomarker, beside FR which already used for RA diagnosis. The serum 
COMP levels were founded higher in the early stage of RA, so it can be 
used to determine the RA severity [18]. The cutoff the serum COMP 
levels in RA patients are still unknown, so we need to compare to the 
normal controls. The serum COMP levels of RA patients was higher than 
the normal control (Table 3).
There were 30% of RA patients were taking the modification joint 
destruction or pain relief, such as injections and joint surgery. The 
serum COMP levels in patients who take the injection or surgery were 
higher than patients who take both injections and surgery (Table 4). 
It showed that the medical treatment is able to modify the disease 
condition and support the COMP as a biomarker of RA activity.
All RA patients were taking disease-modifying antirheumatic drugs 
(DMARDs), nonsteroidal anti-inflammatory drugs, and analgesics. 
Methotrexate (MTX) was proved to modify the development of 
joint damage, which resulting decreased COMP levels along with 
improved joints condition [18]. There were 83.33% of patients were 
prescribed MTX, 13.33% of patients were prescribed a combination 
of MTX and chloroquine (CQ), 13.33% of patients were prescribed a 
combination of MTX and sulfasalazine (SZ), 3.33% of patients were 
prescribed a combination of MTX, CQ, and cyclosporin, and 3.33% of 
patients were prescribed a combination of MTX, SZ, and azathioprine. 
Table 1: DAS 28 of RA patients





Values are mean±SD (n=30). SD: Standard deviation, RA: Rheumatoid arthritis, 
DAS: Disease activity score
Table 2: Subject distribution
Parameter RA patients Normal controls
Mean±SD Range Mean±SD Range
Age (years) 43.77±2.04 20-64 41.23±2.46 21-60
Gender (M/F) 4/26 - 4/26 -
Values are mean±SD (n=30). SD: Standard deviation, RA: Rheumatoid arthritis Fig. 1: Distribution of patients among different age groups (n=30)
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The DMARDs mechanism is to suppress the autoimmune reactivity 
[19]. Most patients (90%) were prescribed methyl prednisolone 
reduce the MTX side, and 33.33% of patients were given analgesics, 
such as paracetamol, ibuprofen, diclofenac sodium, and aspirin. Most 
patients (90%) were also given calcium and folic acid to reduce the 
MTX side effects [20]. The goal of appropriately and routine therapy 
is to maintain the quality of life and stabilize the disease activity. All 
patients were felt the pain when they late in medicine consumption. 
This experience makes patient are compliance to taken the drugs as 
prescribed. These results are consistent with our previous study in 
Purwakarta, Indonesia [21].
The t-test for serum COMP levels of RA patients and normal controls 
showed no difference (p=0.821). It was because of confounding 
variables which make the biased results. If the average of DAS 28 was 
connected to the average serum COMP levels based on disease activity 
category, the results showed that the higher DAS 28, so the higher 
serum COMP levels (Fig. 3). However, if DAS 28 and serum COMP levels 
were connected at any point, the result was no correlation (p=0.496 
and rho=0.129). This is because of the DAS 28 calculation variable 
which involves the ESR that’s not specific to RA inflammation. High ESR 
was predicted obtained from other inflammatory which, experienced 
by the patient because ESR is a general indication of inflammation in 
the body [8].
CONCLUSIONS
There is no correlation between DAS 28 to serum COMP levels in RA 
patients (p=0.496 and rho=0.129).
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